NCT00206726 2016-08-29
ECO-1
Sanofi
Phase 2 Completed
Clinical Trials
6 trialsNCT00046683 2016-07-28
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Sanofi
Phase 3 Completed
NCT00923182 2015-04-30
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sanofi
Phase 1 Completed
NCT00086580 2014-03-13
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
Sanofi
Phase 3 Completed
NCT00328198 2014-03-13
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Phase 2 Completed
NCT00344825 2013-12-04
Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)
Sanofi
Completed